Sirolimus precipitating diabetes mellitus in a patient with congenital hyperinsulinaemic hypoglycaemia due to autosomal dominant ABCC8 mutation

Abstract Background: Sirolimus (mTOR inhibitor) is proven to be effective in children with congenital hyperinsulinism (CHI). Studies in animals suggest that sirolimus may have diabetogenic actions. However, its role in precipitating diabetes mellitus (DM) in children with CHI has not been reported. Case presentation: A 16-year-old female with CHI due to a dominant ABCC8 gene mutation was switched from diazoxide therapy to sirolimus, due to the hypertrichosis side effect of diazoxide. She developed facial cellulitis that was treated with clarithromycin and a month later, once the infection was resolved, she was found to have persistent hyperglycaemia, and was diagnosed with DM. She was unresponsive to oral sulfonylurea therapy and is currently managed with metformin. Her mother, who had the same ABCC8 mutation, developed DM at her 30s. Conclusions: Patients with dominant ABCC8 gene mutations are prone to DM in adulthood, but Sirolimus therapy might increase the risk of developing diabetes at an early age, as this case illustrates.

[1]  J. Rovira,et al.  mTOR Inhibition: Reduced Insulin Secretion and Sensitivity in a Rat Model of Metabolic Syndrome , 2016, Transplantation direct.

[2]  A. Szabó,et al.  Severe Hyperinsulinemic Hypoglycemia in a Neonate: Response to Sirolimus Therapy , 2015, Pediatrics.

[3]  Robert E. Brown,et al.  Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia. , 2014, The New England journal of medicine.

[4]  K. Hussain,et al.  Hyperinsulinaemic Hypoglycaemia: Genetic Mechanisms, Diagnosis and Management , 2012, Journal of clinical research in pediatric endocrinology.

[5]  S. Ellard,et al.  Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant ABCC8/KCNJ11 mutations , 2011, Diabetologia.

[6]  F. Giles,et al.  The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents , 2009, Targeted Oncology.

[7]  Arupa Ganguly,et al.  Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. , 2008, The Journal of clinical investigation.

[8]  A. Webster,et al.  Sirolimus is associated with new-onset diabetes in kidney transplant recipients. , 2008, Journal of the American Society of Nephrology : JASN.

[9]  Christophe Magnan,et al.  mTOR Inhibition by Rapamycin Prevents β-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes , 2008, Diabetes.

[10]  M. Sabbatini,et al.  A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient. , 2007, Current drug metabolism.

[11]  S. di Paolo,et al.  Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes? , 2006, Journal of the American Society of Nephrology : JASN.

[12]  S. di Paolo,et al.  Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. , 2005, Journal of the American Society of Nephrology : JASN.

[13]  C. Stanley,et al.  Clinical and molecular characterization of a dominant form of congenital hyperinsulinism caused by a mutation in the high-affinity sulfonylurea receptor. , 2003, Diabetes.

[14]  H. Huopio,et al.  A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1 , 2003, The Lancet.

[15]  C. Rondinone,et al.  Rapamycin partially prevents insulin resistance induced by chronic insulin treatment. , 2002, Biochemical and biophysical research communications.

[16]  H. Huopio,et al.  Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. , 2000, The Journal of clinical investigation.

[17]  Mackenzie Hs,et al.  Diabetes after Transplantation and Sirolimus: What's the Connection? , 2008 .